Tirzepatide is a drug with dual agonist effects. As a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, it can promote the secretion of first and second phase insulin and reduce plasma glucagon levels (both under glucose-dependent conditions), thereby enhancing insulin secretion, lowering blood sugar levels, and suppressing appetite in a glucose-dependent manner.